Pila Pharma enrolls first participant in PP-CT04 obesity trial of XEN-D0501
Bitget2026/09/30 15:18- Pila Pharma launched dosing for Part 1 of PP-CT04, a 12-week obesity trial of oral candidate XEN-D0501.
- No clinical results have been presented; Part 2 is slated to start once Part 1 clears an internal safety review.
- The study aims to assess safety and tolerability, with additional readouts on drug exposure and efficacy.
- Part 1 uses an eight-participant pilot cohort with intensified safety monitoring before broader enrollment proceeds.
- Dosing uses individual titration to higher target exposures, seeking levels not previously tested in the program.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of England hawkish official: Growth exceeds expectations and employment is resilient, which precisely proves that further rate hikes are necessary.
Megan Greene, a policymaker at the Bank of England, stated that the UK's economic growth surpassing expectations and the resilience of the job market indicate that the Bank of England's efforts to curb inflation are still insufficient.
24 Hour Crypto Recap: Here’s What Happened in the Market
AI investment is reshaping the bond market! Sunak: By 2027, the net issuance of long-term bonds by technology companies may surpass that of the US government
By 2027, tech companies are expected to become larger net issuers of long-term debt than the U.S. government.
Crypto prices
More
